JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

A WIRRAL woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as her having "lumpy boobs" for ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.